Gonococcal Transferrin Binding Protein Chimeras Induce Bactericidal and Growth Inhibitory Antibodies in Mice

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2007 Aug 28

PMID 17720283

Citations 33

Authors

Gregory A Price

Heather P Masri

Aimee M Hollander

Michael W Russell

Cynthia Nau Cornelissen

Affiliations

Soon will be listed here.

Abstract

We have previously demonstrated the full-length gonococcal transferrin binding proteins (TbpA and TbpB) to be promising antigens in the development of a protective vaccine against Neisseria gonorrhoeae. In the current study we employed a genetic chimera approach fusing domains from TbpA and TbpB to the A2 domain of cholera toxin, which naturally binds in a non-covalent fashion to the B subunit of cholera toxin during assembly. For one construct, the N-terminal half of TbpB (NB) was fused to the A2 subunit of cholera toxin. In a second construct, the loop 2 region (L2) of TbpA was genetically fused between the NB domain and the A2 domain, generating a double chimera. Both chimeras were immunogenic and induced serum bactericidal and vaginal growth-inhibiting antibodies. This study highlights the potential of using protective epitopes instead of full-length proteins in the development of an efficacious gonococcal vaccine.

Citing Articles

Dual species transcriptomics reveals conserved metabolic and immunologic processes in interactions between human neutrophils and Neisseria gonorrhoeae.

Potter A, Edwards V, DMello A, Gray M, Shetty A, Forehand A PLoS Pathog. 2024; 20(7):e1012369.

PMID: 38976720 PMC: 11257400. DOI: 10.1371/journal.ppat.1012369.

vaccines: a contemporary overview.

Williams E, Seib K, Fairley C, Pollock G, Hocking J, McCarthy J Clin Microbiol Rev. 2024; 37(1):e0009423.

PMID: 38226640 PMC: 10938898. DOI: 10.1128/cmr.00094-23.

Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy.

Song S, Wang S, Jiang X, Yang F, Gao S, Lin X Emerg Microbes Infect. 2023; 12(2):2249124.

PMID: 37584947 PMC: 10467530. DOI: 10.1080/22221751.2023.2249124.

Editorial: Pathogenic : Pathogenicity, vaccines, and antibiotic resistance.

Arenas J Front Cell Infect Microbiol. 2023; 12:1119244.

PMID: 36683679 PMC: 9850228. DOI: 10.3389/fcimb.2022.1119244.

A New Vaccination Method Based on Phage NgoΦ6 and Its Phagemid Derivatives.

Piekarowicz A, Klyz A, Stein D Front Microbiol. 2022; 13:793205.

PMID: 35572628 PMC: 9096494. DOI: 10.3389/fmicb.2022.793205.

References

Martin M, Hajishengallis G, Metzger D, Michalek S, Connell T, Russell M . Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells. Infect Immun. 2000; 69(1):252-61. PMC: 97879. DOI: 10.1128/IAI.69.1.252-261.2001. View

McClelland R, Wang C, Mandaliya K, Overbaugh J, Reiner M, Panteleeff D . Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS. 2001; 15(1):105-10. DOI: 10.1097/00002030-200101050-00015. View

West D, Reddin K, Matheson M, Heath R, Funnell S, Hudson M . Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun. 2001; 69(3):1561-7. PMC: 98056. DOI: 10.1128/IAI.69.3.1561-1567.2001. View

Masri H, Cornelissen C . Specific ligand binding attributable to individual epitopes of gonococcal transferrin binding protein A. Infect Immun. 2002; 70(2):732-40. PMC: 127705. DOI: 10.1128/IAI.70.2.732-740.2002. View

Matoba N, Magerus A, Geyer B, Zhang Y, Muralidharan M, Alfsen A . A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci U S A. 2004; 101(37):13584-9. PMC: 518798. DOI: 10.1073/pnas.0405297101. View

Russell M, Mestecky J . Humoral immune responses to microbial infections in the genital tract. Microbes Infect. 2002; 4(6):667-77. DOI: 10.1016/s1286-4579(02)01585-x. View

SADLER K, Zeng W, Jackson D . Synthetic peptide epitope-based polymers: controlling size and determining the efficiency of epitope incorporation. J Pept Res. 2002; 60(3):150-8. DOI: 10.1034/j.1399-3011.2002.21009.x. View

Kenney C, Cornelissen C . Demonstration and characterization of a specific interaction between gonococcal transferrin binding protein A and TonB. J Bacteriol. 2002; 184(22):6138-45. PMC: 151950. DOI: 10.1128/JB.184.22.6138-6145.2002. View

Lee S, Halperin S, Salloum D, MacMillan A, Morris A . Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. Infect Immun. 2003; 71(4):2272-5. PMC: 152103. DOI: 10.1128/IAI.71.4.2272-2275.2003. View

10.

Price G, Hobbs M, Cornelissen C . Immunogenicity of gonococcal transferrin binding proteins during natural infections. Infect Immun. 2003; 72(1):277-83. PMC: 343986. DOI: 10.1128/IAI.72.1.277-283.2004. View

11.

Yost-Daljev M, Cornelissen C . Determination of surface-exposed, functional domains of gonococcal transferrin-binding protein A. Infect Immun. 2004; 72(3):1775-85. PMC: 356054. DOI: 10.1128/IAI.72.3.1775-1785.2004. View

12.

Snyder L, Davies J, Saunders N . Microarray genomotyping of key experimental strains of Neisseria gonorrhoeae reveals gene complement diversity and five new neisserial genes associated with Minimal Mobile Elements. BMC Genomics. 2004; 5(1):23. PMC: 406496. DOI: 10.1186/1471-2164-5-23. View

13.

Cornelissen C, Kelley M, Hobbs M, Anderson J, Cannon J, Cohen M . The transferrin receptor expressed by gonococcal strain FA1090 is required for the experimental infection of human male volunteers. Mol Microbiol. 1998; 27(3):611-6. DOI: 10.1046/j.1365-2958.1998.00710.x. View

14.

Gerbase A, Rowley J, Mertens T . Global epidemiology of sexually transmitted diseases. Lancet. 1998; 351 Suppl 3:2-4. DOI: 10.1016/s0140-6736(98)90001-0. View

15.

Retzer M, Yu R, Schryvers A . Identification of sequences in human transferrin that bind to the bacterial receptor protein, transferrin-binding protein B. Mol Microbiol. 1999; 32(1):111-21. DOI: 10.1046/j.1365-2958.1999.01331.x. View

16.

KELLOGG Jr D, PEACOCK Jr W, DEACON W, Brown L, PIRKLE D . NEISSERIA GONORRHOEAE. I. VIRULENCE GENETICALLY LINKED TO CLONAL VARIATION. J Bacteriol. 1963; 85:1274-9. PMC: 278328. DOI: 10.1128/jb.85.6.1274-1279.1963. View

17.

Li X, Erbe J, Lockatell C, Johnson D, Jobling M, Holmes R . Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infect Immun. 2004; 72(12):7306-10. PMC: 529142. DOI: 10.1128/IAI.72.12.7306-7310.2004. View

18.

Jordan P, Snyder L, Saunders N . Strain-specific differences in Neisseria gonorrhoeae associated with the phase variable gene repertoire. BMC Microbiol. 2005; 5:21. PMC: 1097732. DOI: 10.1186/1471-2180-5-21. View

19.

Norheim G, Aase A, Caugant D, Hoiby E, Fritzsonn E, Tangen T . Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine. 2005; 23(29):3762-74. DOI: 10.1016/j.vaccine.2005.02.021. View

20.

Oakhill J, Sutton B, Gorringe A, Evans R . Homology modelling of transferrin-binding protein A from Neisseria meningitidis. Protein Eng Des Sel. 2005; 18(5):221-8. DOI: 10.1093/protein/gzi024. View